Spitfire List Web site and blog of anti-fascist researcher and radio personality Dave Emory.
The tag 'Donald Trump' is associated with 86 posts.

FTR #1152 Bio-Psy-Op Apocalypse Now, Part 12: Covid-19 Updates, Part 3

Flesh­ing out under­stand­ing of Covid-19, this pro­gram looks at the inter­re­la­tion­ship between ele­ments of the mil­i­tary, big phar­ma, ther­a­peu­tic mea­sures select­ed for ear­ly deploy­ment against the “Plan­dem­ic” and the full-court press under­way against Chi­na.

Specif­i­cal­ly, we won­der if the DARPA research into bat-borne coro­n­avirus­es and the appar­ent dis­sem­i­na­tion of Covid-19 as part of the covert oper­a­tions con­stel­la­tion being direct­ed against Chi­na may have dri­ven devel­op­ment of those ther­a­peu­tic mea­sures.

In March of this year, the Pen­ta­gon secured remde­sivir for treat­ing U.S. ser­vice per­son­nel. In FTR #1138, we looked at remde­sivir  being test­ed on rhe­sus macaques in March of 2019. In August of last year, the CDC  closed down the Unit­ed States Army Med­ical Insti­tute of Infec­tious Dis­eases, in part because of defi­cient han­dling of waste pro­duced by “non-human” pri­mates infect­ed with an unnamed “select agent.”

Was that “select agent” Ebo­la? A bat-borne coro­n­avirus? SARS CoV‑2?

Remde­sivir was def­i­nite­ly being test­ed on MERS at a facil­i­ty in Mon­tana that was a base for Willy Burgdor­fer­’s bio­log­i­cal war­fare research result­ing the devel­op­ment of Lyme Dis­ease.

The MERS virus was also a focal point for test­ing of the mes­sen­ger RNA vac­cines being devel­oped (large­ly under DARPA aus­pices). That test­ing appears to have been a fac­tor in fast-track­ing the Mod­er­na vac­cine for SARS CoV‑2 (see below).

Next, we review ele­ments of a thought-pro­vok­ing and dis­turb­ing arti­cle about DARPA research into bat-borne dis­eases, includ­ing some caused by coro­n­avirus­es.

As read­ers digest this infor­ma­tion, remem­ber that DARPA can bring to bear the twined tech­nolo­gies arti­fi­cial intel­li­gence and super-com­put­ers. It has the state of the art with respect to both. Com­bined with gene edit­ing, that tech­no­log­i­cal pair­ing offers the pos­si­bil­i­ty of tru­ly hor­ri­fy­ing syn­thet­ic virus­es.

Whit­ney Webb has pro­vid­ed us with trou­bling insight into Pen­ta­gon research–some of which remains clas­si­fied, includ­ing:

1.–DARPA’s study of “gene-dri­ving tech­nol­o­gy”–” . . . . Con­cerns about Pen­ta­gon exper­i­ments with bio­log­i­cal weapons have gar­nered renewed media atten­tion, par­tic­u­lar­ly after it was revealed in 2017 that DARPA was the top fun­der of the con­tro­ver­sial ‘gene dri­ve’ tech­nol­o­gy, which has the pow­er to per­ma­nent­ly alter the genet­ics of entire pop­u­la­tions while tar­get­ing oth­ers for extinc­tion. . . .”
2.–DARPA’s fund­ing of Mod­er­na’s mRNA vac­cine tech­nol­o­gy.
3.–The clo­sure of the USAMRIID:” . . . . The U.S. Army Med­ical Research Insti­tute of Infec­tious Dis­eases (USAMRIID) facil­i­ty at Fort Det­rick, Mary­land — the U.S. military’s lead lab­o­ra­to­ry for ‘bio­log­i­cal defense’ research since the late 1960s — was forced to halt all research it was con­duct­ing with a series of dead­ly pathogens . . . . USAMRIID has recent­ly been involved in research born out of the Pentagon’s recent con­cern about the use of bats as bioweapons. . . .”

Moderna’s SARS-CoV­‑2 vac­cine con­tin­ues to gen­er­ate con­tro­ver­sy. Despite receiv­ing fund­ing from DARPA, no men­tion of the gov­ern­ment back­ing was men­tioned in its patent fil­ings.

While Mod­er­na was not open about its exten­sive gov­ern­ment sup­port in patent fil­ings, the com­pa­ny has been open about it with the press–for good rea­son: the fast-track­ing of Moderna’s COVID-19 vac­cine devel­op­ment has been jus­ti­fied in large part because of that exten­sive past gov­ern­ment sup­port. That sup­port high­lights the close work Mod­er­na and US gov­ern­ment agen­cies have con­duct­ed togeth­er over the years devel­op­ing this vac­cine tech­nol­o­gy for MERS. Might this devel­op­ment have been part of the DARPA research dis­cussed in the Whit­ney Webb arti­cle?

Next, we high­light a Nature arti­cle from last month describ­ing the exist­ing col­lab­o­ra­tion between the NIAID’s Vac­cine Research Cen­ter and Mod­er­na on a dif­fer­ent vac­cine. Mod­er­na sim­ply shift­ed gears and start­ed work­ing on the COVID-19 vac­cine: it’s been a US government/Moderna col­lab­o­ra­tion from the very begin­ning.

An aspect of Mod­er­na’s vac­cine devel­op­ment that is of con­cern is the fact that mRNA vac­cines are inex­pen­sive to pro­duce, facil­i­tat­ing the pro­duc­tion of large amounts of stock. This, in turn, IF it is announced before elec­tion day, might not only boost Trump’s pop­u­lar­i­ty, but such a devel­op­ment could pro­vide a foun­da­tion for an assault on mail-in vot­ing.

The news out of Moderna’s tri­al could be worse. The extreme­ly small size of this sam­ple, how­ev­er, is a mat­ter of con­cern.

Note­wor­thy in that gen­er­al con­text is the obser­va­tion by Jonathan King (pro­fes­sor of mol­e­c­u­lar biol­o­gy at MIT), that Pen­ta­gon research into the appli­ca­tion of genet­ic engi­neer­ing to bio­log­i­cal war­fare could be masked as vac­cine research, which sounds “defen­sive.”

In FTR #1130, we not­ed the role of four-star gen­er­al Gus­tave Per­na in Trump’s “Oper­a­tion Warp Speed,” insti­tut­ed by Gen­er­al Mark Mil­ley, Chair­man of the Joint Chiefs of Staff.

Whether the pro­gram serves as cov­er for mil­i­tary research seems a rea­son­able ques­tion to ask, under the cir­cum­stances.

We con­clude with a look at the past–a his­tor­i­cal ele­ment of bio­log­i­cal war­fare that reflects on the present.

In past pro­grams and posts, we have briefly not­ed that mil­i­tary and [osten­si­bly] civil­ian pro­grams offi­cial­ly involved with “epi­dem­ic pre­ven­tion” might con­ceal clan­des­tine bio­log­i­cal war­fare appli­ca­tions designed to cre­ate epi­demics.

The offi­cial dis­tinc­tion between “offen­sive” and “defen­sive” bio­log­i­cal war­fare research is aca­d­e­m­ic.

In that con­text, one should note that the offi­cial title of Unit 731, the noto­ri­ous Japan­ese bio­log­i­cal war­fare unit was “the Epi­dem­ic Pre­ven­tion and Water Purifi­ca­tion Depart­ment of the Kwan­tung Army.”

The Whit­ney Webb article–once again–figures into this analy­sis:

The DARPA research is osten­si­bly aimed at pre­vent­ing pan­demics but–very possibly–masking prepa­ra­tions for offen­sive bio­log­i­cal war­fare projects. ” . . . . Many of these recent research projects are relat­ed to DARPA’s Pre­vent­ing Emerg­ing Path­o­gen­ic Threats, or PREEMPT pro­gram, which was offi­cial­ly announced in April 2018. PREEMPT focus­es specif­i­cal­ly on ani­mal reser­voirs of dis­ease, specif­i­cal­ly bats, and DARPA even not­ed in its press release in the pro­gram that it ‘is aware of biosafe­ty and biose­cu­ri­ty sen­si­tiv­i­ties that could arise’ due to the nature of the research. . . . In addi­tion, while both DARPA’s PREEMPT pro­gram and the Pentagon’s open inter­est in bats as bioweapons were announced in 2018, the U.S. mil­i­tary — specif­i­cal­ly the Depart­ment of Defense’s Coop­er­a­tive Threat Reduc­tion Pro­gram — began fund­ing research involv­ing bats and dead­ly pathogens, includ­ing the coro­n­avirus­es MERS and SARS, a year pri­or in 2017. . . .”

FTR #1151 Bio-Psy-Op Apocalypse Now, Part 11: Covid-19 Updates, Part 2

Con­tin­u­ing our inquiry into the Covid-19 pan­dem­ic, this pro­gram con­tin­ues analy­sis of the dis­ease as a “plandemic”–a bio­log­i­cal war­fare man­i­fes­ta­tion that is one part act of war, one part domes­tic ter­ror­ism, and a major “psy-op.”

The wide­ly pub­li­cized inter­view Trump gave to Bob Wood­ward, in which Trump can­did­ly assessed the lethal nature of SARS Cov‑2 has been mis­un­der­stood. Trump’s pol­i­cy on the virus has been just exact­ly what he and the inter­ests for which he fronts desire.

The Plan­dem­ic is a por­tal for the real­iza­tion of the goals of the Under­ground Reich for which Trump is a front man and enabler. These issues either have been or will be dis­cussed at greater length.

The virus is the Wealth Con­cen­tra­tion Virus.
It is the Wealth-Destroy­ing Virus for areas and insti­tu­tions that the Trump inter­ests oppose.
It is the Urban Area Destruc­tion Virus.
It is the White Suprema­cist Virus–hitting peo­ple of col­or much hard­er, due to health and socio-eco­nom­ic fac­tors.
It is the Eugenic Virus–killing old­er peo­ple and peo­ple with com­pli­cat­ing med­ical con­di­tions.
It is the Edu­ca­tion-Destroy­ing Virus, dras­ti­cal­ly and neg­a­tive­ly affect­ing pub­lic schools and col­leges.
It is the Pub­lic Tran­sit Destroy­ing Virus.
It is the Divide and Con­quer Virus–separating the old from the young and–potentially–women from men.
The Plan­dem­ic is the “Bio-Psy-Op Apoc­a­lypse” Virus, rav­aging the psy­ches of indi­vid­u­als and groups.
Trump kept a copy of this by his bed­side for late-night read­ing.

The Covid-19 pan­dem­ic is dri­ving what might be termed a right-wing ide­o­log­i­cal wet dream in a num­ber of dif­fer­ent respects. Here, we note that the dam­age done by the virus is seen as fur­ther­ing a cor­po­ratist agen­da, mas­querad­ing under the com­mon rhetor­i­cal cam­ou­flage of “lib­er­tar­i­an” phi­los­o­phy.

An impor­tant piece in “The Guardian” details how plu­to­crats terming them­selves “anar­cho-cap­i­tal­ists” see the pan­dem­ic as forc­ing regions–from nations to municipalities–to con­form to the demands of dom­i­nant, mobile blocks of cap­i­tal by elim­i­nat­ing the essen­tials of the pro­gres­sive social agen­da.

1.–” . . . . They spy oppor­tu­ni­ty in the cri­sis, and wager that we might be able to ride the wave of the pan­dem­ic into a new tomor­row, where the virus shat­ters the glob­al map – and under­mines the pow­er of demo­c­ra­t­ic nation states. The US is ground zero for this type of think­ing. . . .”
2.–” . . . . In an analy­sis released at the end of April, Arthur Laf­fer and Stephen Moore, two of Trump’s clos­est eco­nom­ic con­fi­dants and authors of the book on ‘Trumpo­nom­ics’, pre­dict­ed that ‘blue’ Demo­c­ra­t­ic states would be slow­er than ‘red’ states to recov­er, because of what they saw as their pre-exist­ing excess of reg­u­la­tions and tax­es. . . .”
3.–” . . . .Their analy­sis divid­ed the US map into ‘lag­gard anti-growth’ states and ‘momen­tum pro-growth’ states. The for­mer have min­i­mum wages, pro-union laws and state income tax; the lat­ter are free of such reg­u­la­tions. In the estab­lished mode of dis­as­ter cap­i­tal­ism, Laf­fer and Moore’s analy­sis appears to see the pan­dem­ic as a way to com­pel ‘anti-growth’ states to adopt ever low­er tax rates in order to attract mobile cap­i­tal and labour. It sug­gests those who resist will not be bailed out by redis­tri­b­u­tion from the cen­tral gov­ern­ment, but left to lan­guish in a deserved eco­nom­ic depres­sion. The effect is rem­i­nis­cent of social Dar­win­ism, applied as a phi­los­o­phy of gov­ern­ment. . . .”
4.–” . . . . As nations are divid­ed into dif­fer­ent zones accord­ing to their respec­tive stages of viral and eco­nom­ic recov­ery, the well-off could fol­low Elon Musk’s recent threat to relo­cate from Cal­i­for­nia to Texas, vot­ing with their feet for loca­tions that elude redis­trib­u­tive tax­a­tion. In our post-pan­dem­ic future, the flight to safe­ty, away from con­ta­gious ‘red zones’, could be a flight from the nation state as we know it. . . .”

As an intro­duc­tion, we review key aspects of a very impor­tant arti­cle by Whit­ney Webb, set­ting forth exten­sive DARPA research into bat-borne coro­n­avirus­es, poten­tial­ly geno­ci­dal gene-dri­ving tech­nol­o­gy and over­lap­ping research into vac­cine devel­op­ment, as well as the pos­si­bil­i­ty that such research may have been involved with the CDC’s shut­down of Fort Det­rick­’s USAMRIID in ear­ly August of 2019.

In numer­ous pro­grams, we have not­ed remde­sivir and how it has driven–very pos­si­bly with insid­er advanced knowl­edge and trading–the stock mar­ket. We have cov­ered remde­sivir and Gilead Sci­ences in detail in FTR #‘s 1132, 1134, and 1138.

The FDA–now head­ed by the Hoover Insti­tute’s Stephen Hahn, a for­mer can­cer spe­cial­ist with no expe­ri­ence in infec­tious diseases–has expand­ed the approved use of remde­sivir. Experts are warn­ing that the FDA pro­vid­ed no data jus­ti­fy­ing the move and now the drug is going to be in even short­er sup­ply for the sick­est patients.

The remain­der of the pro­gram focus­es on fast-track­ing of vac­cines.

Among the gam­bits being dis­cussed as pos­si­ble vehi­cles for Trump to gain a sec­ond term is the roll­out of a Covid-19 vac­cine. The CDC has told states to pre­pare for such a devel­op­ment. Many crit­ics have cit­ed the pre­ma­ture nature of such a pos­si­bil­i­ty and the lack of ade­quate test­ing.

Next, we present an inter­view of the head of the FDA, Stephen Hahn, about his will­ing­ness to fast-track a vac­cine. The way Hahn puts it, the cri­te­ria for his deci­sion to fast track is sim­ply as long as the ben­e­fits out­weigh the risks.

Hahn comes from the Hoover Insti­tute. His med­ical expe­ri­ence is in the field of can­cer treat­ment. He has no expe­ri­ence in infec­tious dis­eases.

As crit­ics point out, even if ear­ly results are over­whelm­ing­ly pos­i­tive that doesn’t pre­clude the pos­si­bil­i­ty of dan­ger­ous side effects tak­ing longer to man­i­fest. In addi­tion, end­ing the tri­al ear­ly reduces oppor­tu­ni­ty to recruit more peo­ple from groups cur­rent­ly under-rep­re­sent­ed in tri­als, such as blacks and His­pan­ics. End­ing the tri­als ear­ly due to very pos­i­tive ini­tial results might hide dele­te­ri­ous results down the line, par­tic­u­lar­ly for the non-whites that Trump and his base despise.

Antho­ny Fau­ci has indi­cat­ed the pos­si­bil­i­ty of such an ear­ly autho­riza­tion.

Next, we present an inter­view with Trump’s pre­vi­ous FDA chief, Scott Got­tlieb, who sits on the board of Pfizer–along with Mod­er­na, lead­ing the race to get a vac­cine to mar­ket.

One sce­nario he saw as fea­si­ble for a pre-elec­tion vac­cine release: if clin­i­cal tri­als demon­strate that the vac­cine is high­ly effec­tive in the mid­dle of a new “dense” wave of cas­es.

FTR #1150 The Space Plane and Covid-19: The Paperclip Legacy, Part 5

This pro­gram com­pletes the line of inquiry we under­took in FTR #‘s 1146, 1147, 1148 and 1149. Most impor­tant­ly, we bring the evo­lu­tion of events and insti­tu­tions up to the present. Lis­ten­ers who digest the pro­grams in the future should bear in mind that these pro­grams were record­ed dur­ing, and the imme­di­ate after­math of, the 2020 GOP con­ven­tion.

After review­ing infor­ma­tion about Nixon con­fi­dante Bebe Rebo­zo and the links of his bank to the dead­ly Bor­mann net­work, we con­tin­ue with the unpub­lished man­u­script from which we read in our last pro­gram. The broad­cast high­lights inter­ac­tions between the Nixon admin­is­tra­tion, Bebe Rebo­zo, a mys­te­ri­ous and alleged­ly orga­nized-crime con­nect­ed com­pa­ny called Resorts Inter­na­tion­al, an even more mys­te­ri­ous sub­sidiary of Resorts Inter­na­tion­al called the Par­adise Island Bridge Com­pa­ny and the Dewey, Dulles, Nazi, William Casey milieu that is cen­tral to this dis­cus­sion.

The Par­adise Island Bridge Com­pa­ny’s direc­tors are sug­ges­tive of a pos­si­ble Bor­mann link: ” . . . . It did, how­ev­er, name a num­ber of Ger­man and Swiss investors, One of these, for exam­ple, was Dr. Heinz Ros­terg of Lau­sanne, a for­mer ‘prin­ci­pal stock­hold­er’ and direc­tor of the Win­ter­shall potash con­cern; Win­ter­shall was one of the major sub­sidiaries of BASF, the largest sin­gle suc­ces­sor firm to I.G. Far­ben. . . . .”

Allen Dulles

The man­u­script sets forth spec­u­la­tion about the pos­si­bil­i­ty that Mary Carter Paint/Resorts Inter­na­tion­al may have gen­er­at­ed funds that greased the wheels for the release of many Nazi war crim­i­nals. ” . . . . Still unan­swered is the ques­tion of whether the sto­ry of the Dewey-Allen Dulles inter­est in Resorts should have referred to funds, not from the CIA itself, but from its Ger­man-Swiss part­ners in the Par­adise Island Bridge Com­pa­ny. Such a hypoth­e­sis might explain some of the many strange coin­ci­dences which sur­round the com­pa­ny’s con­tro­ver­sial his­to­ry. It might, for exam­ple, explain the ‘for­tune in legal fees’ that Mary Carter Paint, on the advice of Thomas Dewey, paid to Allen Dulles’ long­time law part­ner David Peck. (48) The SS-OSS con­nec­tion cer­tain­ly had rea­son to be grate­ful to David Peck. It was on the basis of Peck­’s rec­om­men­da­tion, as chair­man of a three-man advi­so­ry board to review all the Nurem­berg sen­tences, that John J. McCloy com­mut­ed to time served the sen­tence of Sko­rzeny’s post-war employ­er, Baron Alfried Krupp, and eight of his col­leagues, and also ordered Krup­p’s prop­er­ty to be restored. (49) The release of Krupp and oth­er indus­tri­al­ists ful­filled an ear­li­er demand to McCloy from Her­mann Abs, who him­self nar­row­ly escaped pros­e­cu­tion at Nurem­berg. Abs was the first post-war chair­man of BASF, the I.G. Far­ben suc­ces­sor com­pa­ny rep­re­sent­ed among the stock­hold­ers of the Par­adise Island Bridge Com­pa­ny. (50) . . . .”

William Casey

The author also engages in spec­u­la­tion about the rela­tion­ship between Resorts Inter­na­tion­al and Cap­i­tal Cities Broad­cast­ing. The lat­ter is the com­pa­ny that bought out ABC in the mid 1980’s and whose largest stock­hold­er was William Casey. ” . . . . Might not the OSS-SS con­nec­tion also throw light on the unex­plained inter­lock between James Cros­by’s com­pa­ny Resorts Inter­na­tion­al, tight­ly con­trolled by the relat­ed and dou­bly inter­mar­ried Cros­by-Mur­phy fam­i­lies, and Cap­i­tal Cities Broad­cast­ing, the major invest­ment of the CIA’s present direc­tor William Casey. (51) Casey would be the log­i­cal per­son to have estab­lished the orig­i­nal con­nec­tion between the Cros­by-Mur­phy fam­i­lies and their mys­te­ri­ous Ger­man-Swiss part­ners. For it was Casey who, in 1944–45, ‘was giv­en over­all oper­a­tional con­trol of [OSS] Ger­man projects,’ and ‘co-ordi­nat­ed . . . the over 150 men’ whom OSS sent into Ger­many. (52) With Dulles, Wis­ner, and For­gan, Casey was also one of the OSS vet­er­ans who lob­bied suc­cess­ful­ly for a CIA which could legit­i­mate­ly uti­lize the resources of the Gehlen Org. (53) . . .”

The “unex­plained inter­lock” between Resorts Inter­na­tion­al and Cap­i­tal Cities is described by the author: ” . . . . James Cros­by’s cousin and broth­er-in-law, Thomas S. Mur­phy, was in 1964, the Exec­u­tive Vice-Pres­i­dent and a direc­tor of Cap­i­tal Cities, as well as a direc­tor of Mary Carter Paint. Low­ell Thomas, a long-time radio broad­cast­er with intel­li­gence con­nec­tions, was a direc­tor of both com­pa­nies. At the time, William Casey was an offi­cer, direc­tor, and major stock­hold­er of Cap­i­tal Cities. . . .”

Trump kept a copy of this by his bed­side for late-night read­ing.

After James Cros­by’s “unex­pect­ed” death in April of 1986, Don­ald Trump–whose oper­a­tions are bankrolled by Deutsche Bank–purchased the com­pa­ny. Fol­low­ing lit­i­ga­tion with Merv Grif­fin, the assets were divid­ed with the tele­vi­sion per­son­al­i­ty. ”  . . . . Real estate devel­op­er Don­ald Trump, who owned two Atlantic City casi­nos, beat out sev­er­al oth­er bid­ders to pur­chase a con­trol­ling stake in the com­pa­ny from Cros­by’s fam­i­ly for $79 mil­lion in July 1987.[26] Trump was appoint­ed chair­man of Resorts Inter­na­tion­al, and said he would com­plete the Taj Mahal in about a year. . . . The two ulti­mate­ly reached a set­tle­ment, which was exe­cut­ed in Novem­ber 1988, with Grif­fin pur­chas­ing the com­pa­ny for $365 mil­lion, and Trump pur­chas­ing the Taj Mahal from the com­pa­ny for $273 mil­lion. . . .”

Pro­gram High­lights Include:

1.–Discussion of Cap­i­tal Cities Broad­cast­ing’s acqui­si­tion of ABC fol­low­ing the CIA’s fil­ing of a “fair­ness doc­trine” com­plaint against the com­pa­ny for their cov­er­age of Bish­op, Bald­win, Rewald, Dilling­ham and Wong. Ron Rewald alleged that he and the firm for which he worked front­ed for CIA. (At the time William Casey was head of CIA and Cap­i­tal Cities largest stock­hold­er.)
2.–The fact that Thomas Dewey, two time GOP can­di­date for Pres­i­dent, was one of the founders of Cap­i­tal Cities. The gen­e­sis of the Nazi branch of the GOP was Dewey’s 1948 cam­paign.
3.–Review of William Casey’s career, includ­ing the posi­tions he held in the Nixon admin­is­tra­tion and his involve­ment with the Black Eagle Trust, which evolved from the Gold­en Lily plun­der acquired by Japan after World War II.
4.–Discussion of Attor­ney Gen­er­al William Bar­r’s back­ground in the CIA, includ­ing his role in George H.W. Bush’s par­don of key play­ers in the Iran-Con­tra scan­dal.
5.–Analysis of Bar­r’s father Don­ald Barr and his work for the OSS in World War II, which may have inter­sect­ed with the machi­na­tions of Dulles, Dono­van, Casey and the Nazi “Oper­a­tion Sun­rise” par­tic­i­pants.
6.–Donald Bar­r’s hir­ing of col­lege dropout Jef­frey Epstein to teach at the Dal­ton School.
7.–Donald Bar­r’s author­ship of a sci­ence fic­tion novel–Space Relations–about a plan­et dom­i­nat­ed by oli­garchs and dri­ven by sex­u­al slav­ery.
8.–Review of a deci­sive strat­a­gem of the Under­ground Reich, enun­ci­at­ed by Army offi­cer Glenn Pinch­back in a let­ter to New Orleans D.A. Jim Gar­ri­son. Pinch­back wrote of a ” . . . . ‘Neo-Nazi plot to enslave Amer­i­ca in the name of anti-Com­mu­nism,’ . . .”
9.–In past pro­grams, we have briefly not­ed that mil­i­tary and [osten­si­bly] civil­ian pro­grams offi­cial­ly involved with “epi­dem­ic pre­ven­tion” might con­ceal clan­des­tine bio­log­i­cal war­fare appli­ca­tions designed to cre­ate epi­demics. The offi­cial dis­tinc­tion between “offen­sive” and “defen­sive” bio­log­i­cal war­fare research is aca­d­e­m­ic. In that con­text, one should note that the offi­cial title of Unit 731, the noto­ri­ous Japan­ese bio­log­i­cal war­fare unit was “the Epi­dem­ic Pre­ven­tion and Water Purifi­ca­tion Depart­ment of the Kwan­tung Army.” Unit 731’s research was incor­po­rat­ed into the U.S. bio­log­i­cal war­fare pro­gram at the end of World War II.
10.–Noteworthy in that gen­er­al con­text is the obser­va­tion by Jonathan King (pro­fes­sor of mol­e­c­u­lar biol­o­gy at MIT), that Pen­ta­gon research into the appli­ca­tion of genet­ic engi­neer­ing to bio­log­i­cal war­fare could be masked as vac­cine research, which sounds “defen­sive.”

FTR #1139 The Anthrax Attacks, the Invasion of Iraq and Expansion of Biological Warfare Capabilities

As the title indi­cates, this pro­gram presents polit­i­cal and his­tor­i­cal foun­da­tion for the expo­nen­tial expan­sion of Amer­i­can bio­log­i­cal war­fare infra­struc­ture fol­low­ing the 2001 anthrax attacks.

Impor­tant back­ground infor­ma­tion comes from the Whit­ney Webb arti­cle about DARPA spend­ing on bat-borne coro­n­avirus­es.

The Broad­cast­ing Board of Governors–a CIA “derivative”–and The Wash­ing­ton Times (owned by the Uni­fi­ca­tion Church) helped devel­op dis­in­for­ma­tion about SARS CoV‑2 com­ing from a Chi­nese Bio­log­i­cal War­fare lab. Both were instru­men­tal in hyp­ing the anthrax attacks as authored by Sad­dam Hus­sein, as well. The Wash­ing­ton Times also pre­sent­ed infor­ma­tion float­ed by Steven Hat­fill that fore­shad­owed sub­se­quent charges that Sad­dam Hus­sein was devel­op­ing bioweapons and was behind the 2001 anthrax attacks.

In addi­tion, the Project For a New Amer­i­can Cen­tu­ry was advanc­ing an agen­da in which genet­i­cal­ly-engi­neered bio­log­i­cal war­fare tech­nol­o­gy as essen­tial to con­tin­ued Amer­i­can glob­al dom­i­nance.

As will be seen below, a key func­tionary in the PNAC milieu was for­mer Sec­re­tary of Defense Don­ald Rums­feld, for­mer chair­man of the board of Gilead Sci­ences.

In FTR #‘s 1135, 1136 and 1137, we relied heav­i­ly on the Kris New­by’s Bit­ten: The Secret His­to­ry of Lyme Dis­ease and Bio­log­i­cal Weapons. In that book, Ms. New­by net­worked with a group of expe­ri­enced, Cold War bio­log­i­cal war­fare pro­fes­sion­als whom she termed “the Brain Trust.” They were con­vinced that Fort Det­rick sci­en­tist Bruce Ivins–the “lone nut” who con­ve­nient­ly com­mit­ted sui­cide and was fin­gered as the sole per­pe­tra­tor of the 2001 anthrax attacks–was framed. ” . . . . Among oth­er sub­jects, they dis­cussed  . . . tech­ni­cal details on why they believed that their col­league Bruce Ivins had been framed as the anthrax mail­er . . . .”

Much of the pro­gram cen­ters on the 2001 attacks and the sus­pi­cion that focused on Steven Hat­fill as a pos­si­ble per­pe­tra­tor of them. Although exon­er­at­ed in the attacks, Hat­fill was the focal point of con­sid­er­able sus­pi­cion in con­nec­tion with the event. Our sus­pi­cion is that he is an oper­a­tive of one or anoth­er intel­li­gence agency, CIA being the most prob­a­ble.

We sus­pect that the anthrax attacks were a provo­ca­tion aimed at jus­ti­fy­ing the inva­sion of Iraq and spurring devel­op­ment of the U.S. bio­log­i­cal war­fare capa­bil­i­ty.

Of par­tic­u­lar note is the appar­ent “oper­a­tional Teflon” worn by Hat­fill. Although cir­cum­stan­tial evi­dence point­ed in his direc­tion, he appeared to be alto­geth­er “off lim­its” to inves­tiga­tive ele­ments of Alpha­bet Soup. Don Fos­ter not­ed the unusu­al treat­ment accord­ed to Hat­fill by the pow­ers that be.

Of sig­nif­i­cance, as well, are the numer­ous exam­ples of fore­shad­ow­ing of the foren­sic cir­cum­stances of the anthrax attacks, as well as oth­er “false alarm” inci­dents that occurred before and after the fatal attacks. It requires lit­tle to see state­ments and arti­cles by nota­bles such as Bill Patrick and the seem­ing­ly ubiq­ui­tous Steven Hat­fill as lay­ing a foun­da­tion of cred­i­bil­i­ty for sub­se­quent events.

Note that the Nation­al Insti­tutes of Health have also part­nered with CIA and the Pen­ta­gon, as under­scored by an arti­cle about a BSL‑4 lab at Boston Uni­ver­si­ty.

1.–As the arti­cle notes, as of 2007, the U.S. had “more than a dozen” BSL4 labs–China com­mis­sioned its first as of 2017. a ten­fold increase in fund­ing for BSL4 labs occurred because of the anthrax attacks of 2001. Those attacks might be seen as some­thing of a provo­ca­tion, spurring a dra­mat­ic increase in “dual use” biowar­fare research, under the cov­er of “legit­i­mate” medical/scientific research. In FTR #1128, we hypoth­e­sized about the milieu of Steven Hat­fill and apartheid-linked inter­ests as pos­si­ble authors of a vec­tor­ing of New York City with Sars COV2: ” . . . . Before the anthrax mail­ings of 2001, the Unit­ed States had just two BSL4 labs—both with­in the razor-wire con­fines of gov­ern­ment-owned cam­pus­es. Now, thanks to a ten­fold increase in funding—from $200 mil­lion in 2001 to $2 bil­lion in 2006—more than a dozen such facil­i­ties can be found at uni­ver­si­ties and pri­vate com­pa­nies across the coun­try. . . .”
2.–The Boston Uni­ver­si­ty lab exem­pli­fies the Pen­ta­gon and CIA pres­ence in BSL‑4 facil­i­ty “dual use”: ” . . . . But some sci­en­tists say that argu­ment obscures the true pur­pose of the cur­rent biode­fense boom: to study poten­tial bio­log­i­cal weapons. ‘The uni­ver­si­ty por­trays it as an emerg­ing infec­tious dis­ease lab,’ says David Ozonoff, a Boston Uni­ver­si­ty epi­demi­ol­o­gist whose office is right across the street from the new BSL4 facil­i­ty. ‘But they are talk­ing about study­ing things like small pox and inhala­tion anthrax, which pose no pub­lic health threat oth­er than as bioweapons.’ . . . The orig­i­nal NIH man­date for the lab indi­cat­ed that many groups—including the CIA and Depart­ment of Defense—would be allowed to use the lab for their own research, the nature of which BU might have lit­tle con­trol over. . . .”

As not­ed in past pro­grams, Gilead Sci­ences is very well-con­nect­ed pro­fes­sion­al­ly, with for­mer Sec­re­tary of Defense Don­ald Rums­feld (among oth­er polit­i­cal lumi­nar­ies) serv­ing on its board of direc­tors. Rums­feld was chair­man of the board from 1997 until he left in 2001 to become George W. Bush’s Sec­re­tary of Defense.

Rums­feld was Sec­re­tary of Defense dur­ing the peri­od in which the 2001 anthrax attacks occurred.

Dur­ing the post‑9/11 peri­od of explod­ing gov­ern­ment invest­ments in biode­fense pro­grams, Sec­re­tary of Defense Don­ald Rums­feld was still hold­ing onto mas­sive amounts of Gilead stock, which was increas­ing in val­ue dra­mat­i­cal­ly. What kind of rela­tion­ship did Gilead devel­op with the US biode­fense nation­al secu­ri­ty state dur­ing this peri­od? That seems like a pret­ty impor­tant ques­tion at this point in time.

The U.S. gov­ern­ment was among the cus­tomers whose pur­chas­es drove up the Gilead earn­ings and stock price: ” . . . . What’s more, the fed­er­al gov­ern­ment is emerg­ing as one of the world’s biggest cus­tomers for Tam­i­flu. In July, the Pen­ta­gon ordered $58 mil­lion worth of the treat­ment for U.S. troops around the world, and Con­gress is con­sid­er­ing a mul­ti-bil­lion dol­lar pur­chase. . . .”

Sev­er­al years into his tenure at the Pen­ta­gon, Rums­feld made a killing on the sale of Gilead Sci­ences’ stock, which rose expo­nen­tial­ly in val­ue fol­low­ing its devel­op­ment of Tam­i­flu as a treat­ment for H5N1 avian flu.” . . . . The firm made a loss in 2003, the year before con­cern about bird flu start­ed. Then rev­enues from Tam­i­flu almost quadru­pled, to $44.6m, help­ing put the com­pa­ny well into the black. Sales almost quadru­pled again, to $161.6m last year. Dur­ing this time the share price tre­bled. Mr Rums­feld sold some of his Gilead shares in 2004 reap­ing – accord­ing to the finan­cial dis­clo­sure report he is required to make each year – cap­i­tal gains of more than $5m. The report showed that he still had up to $25m-worth of shares at the end of 2004, and at least one ana­lyst believes his stake has grown well beyond that fig­ure, as the share price has soared. . . .”

Don­ald Rums­feld was a sig­na­to­ry to the 1998 let­ter to Pres­i­dent Clin­ton by the Project for a New Amer­i­can Cen­tu­ry. That let­ter advo­cat­ed a hard­er line against Iraq. ” . . . . Rums­feld has strong ties to the Intel­li­gence Com­mu­ni­ty, as well as to the Atlantic Insti­tute, and is a mem­ber of the Bilder­berg group. He is a finan­cial sup­port­er for the Cen­ter for Secu­ri­ty Pol­i­cy. Rums­feld was one of the sign­ers of the Jan­u­ary 26, 1998, Project for the New Amer­i­can Cen­tu­ry (PNAC) let­ter sent to Pres­i­dent William Jef­fer­son Clin­ton. . . .”

DARPA and the Pen­ta­gon have into the appli­ca­tion of genet­ic engi­neer­ing in order to cre­ate eth­no-spe­cif­ic bio­log­i­cal war­fare weapons, as dis­cussed by the Project for a New Amer­i­can Cen­tu­ry.

In past pro­grams and posts, we have not­ed that DARPA was research­ing  bat-borne coro­n­avirus­es.  One can but won­der to what extent the PNAC doc­trine helped spawn the DARPA research into coro­n­avirus­es and, pos­si­bly, the Covid-19 pan­dem­ic.

FTR #1138 Bio-Psy-Op Apocalypse Now, Part 10: Bad Medicine

Con­tin­u­ing dis­cus­sion about drug treat­ments for, and vac­cines to pre­vent, Covid-19, this pro­gram sets forth infor­ma­tion about the ongo­ing pro­fes­sion­al mas­sag­ing of Gilead Sci­ences’ anti-viral remde­sivir. Only mod­est­ly suc­cess­ful against SARS Cov‑2 (the virus that caus­es Covid-19), remde­sivir has been pro­pelled to the fore­front of treat­ment reg­i­mens for the pan­dem­ic.

Of par­tic­u­lar inter­est are the cir­cum­stances sur­round­ing the CDC’s clo­sure of the U.S. Army Med­ical Research Insti­tute of Infec­tious Dis­eases. The USAMRIID–located at Ft. Detrick–had host­ed Gilead Sci­ences’ ani­mal tri­als of remde­sivir. Remde­sivir was devel­oped to com­bat Ebo­la, and was a fail­ure in its ini­tial pro­fes­sion­al iter­a­tion.

In March of 2019, rhe­sus macaques were infect­ed with Ebo­la at the USAMRIID as part of a project to allow remde­sivir to be mar­ket­ed as an Ebo­la treat­ment with­out meet­ing the pro­fes­sion­al stan­dards of human test­ing. ” . . . This agree­ment was made pos­si­ble through a 2018 Nat­ur­al His­to­ry Study (NHS) of Ebo­la virus con­duct­ed by USAMRIID in close col­lab­o­ra­tion with Gilead Sci­ences, Inc., the spon­sor of remde­sivir devel­op­ment . . .”

Many of the safe­ty vio­la­tions cit­ed by the CDC in its cri­tique of USAMRIID safe­ty and secu­ri­ty pro­ce­dures con­cerned “non-human pri­mates” infect­ed with one or more “select agents” that were not named. The term “select agent” refers to a pathogen being used in lab­o­ra­to­ry pro­ce­dures. Whether the “select agent” was Ebo­la, and whether the safe­ty laps­es were in con­nec­tion with the remdesivir/rhesus mon­key tri­als was not dis­closed.

” . . . . Sev­er­al of the lab­o­ra­to­ry vio­la­tions the CDC not­ed in 2019 con­cerned ‘non-human pri­mates’ infect­ed with a ‘select agent’, the iden­ti­ty of which is unknown — it was redact­ed in all received doc­u­ments, because dis­clos­ing the iden­ti­ty and loca­tion of the agent would endan­ger pub­lic health or safe­ty, the agency says. In addi­tion to Ebo­la, the lab works with oth­er dead­ly agents like anthrax and small­pox. . . ..”

If, for the sake of argu­ment, SARS-CoV­‑2 research was indeed tak­ing plac­ing there was a very real risk of it escap­ing.

Remde­sivir failed in its human tri­als as a treat­ment for Ebo­la: ” . . . . The antivi­ral drug remde­sivir, made by Gilead, under­per­formed ZMapp. . . .  Remde­sivir and ZMapp have been dropped from the tri­al. . . .”

Fol­low­ing that dis­mal per­for­mance against Ebo­la, Gilead Sci­ences recast remde­sivir as a broad spec­trum antivi­ral, a mar­ket­ing approach that has led to the drug being autho­rized to treat Covid-19.

In that pro­fes­sion­al rein­car­na­tion, it demon­strat­ed alto­geth­er mod­est suc­cess in Covid-19 tri­als that were pro­fes­sion­al­ly crit­i­cized and which were bad­ly skewed from a method­olog­i­cal stand­point. 

After a tight­en­ing of pro­fes­sion­al method­olog­i­cal stan­dards at the USAMRIID, it was dis­closed that most of the insti­tu­tion’s oper­a­tives are pri­vate con­trac­tors! From the stand­point of insti­tu­tion­al secu­ri­ty, the broad use of pri­vate con­trac­tors ren­ders USAMRIID sub­ject to pen­e­tra­tion by any num­ber of poten­tial mis­cre­ants. ” . . . . ‘A major­i­ty of our lab­o­ra­to­ry work­ers are contractors–putting teeth in the con­tracts to ensure they’re fol­low­ing the shalls, wills and musts are things we’ve done in the inter­im,’ said [Brigadier Gen­er­al Mike] Tal­ley. . . .”

As not­ed in past pro­grams, Gilead Sci­ences is very well-con­nect­ed pro­fes­sion­al­ly, with for­mer Sec­re­tary of Defense Don­ald Rums­feld (among oth­er polit­i­cal lumi­nar­ies) serv­ing on its board of direc­tors. Rums­feld was chair­man of the board from 1997 until he left in 2001 to become George W. Bush’s Sec­re­tary of Defense. The fir­m’s stock has been heav­i­ly invest­ed in by hedge funds, includ­ing Robert Mer­cer’s Renais­sance Tech­nolo­gies. Gilead Sci­ences’ stock has been a major dri­ver of the stock mar­ket’s per­for­mance.

Sev­er­al years into his tenure at the Pen­ta­gon, Rums­feld made a killing on the sale of Gilead Sci­ences’ stock, which rose expo­nen­tial­ly in val­ue fol­low­ing its devel­op­ment of Tam­i­flu as a treat­ment for H5N1 avian flu. ” . . . . The firm made a loss in 2003, the year before con­cern about bird flu start­ed. Then rev­enues from Tam­i­flu almost quadru­pled, to $44.6m, help­ing put the com­pa­ny well into the black. Sales almost quadru­pled again, to $161.6m last year. Dur­ing this time the share price tre­bled. Mr Rums­feld sold some of his Gilead shares in 2004 reap­ing – accord­ing to the finan­cial dis­clo­sure report he is required to make each year – cap­i­tal gains of more than $5m. The report showed that he still had up to $25m-worth of shares at the end of 2004, and at least one ana­lyst believes his stake has grown well beyond that fig­ure, as the share price has soared. . . .”

The U.S. gov­ern­ment was among the cus­tomers whose pur­chas­es drove up the Gilead earn­ings and stock price: ” . . . . What’s more, the fed­er­al gov­ern­ment is emerg­ing as one of the world’s biggest cus­tomers for Tam­i­flu. In July, the Pen­ta­gon ordered $58 mil­lion worth of the treat­ment for U.S. troops around the world, and Con­gress is con­sid­er­ing a mul­ti-bil­lion dol­lar pur­chase. . . .”

(Recall that the H5N1 virus is one of the gain-of-func­tion exper­i­ments that was sus­pend­ed in 2014 and then green­light­ed by the Trump admin­is­tra­tion in 2017. Those exper­i­ments engi­neered the virus to infect fer­rets, a maneu­ver that made the virus com­mu­ni­ca­ble by upper res­pi­ra­to­ry activ­i­ty. One can but won­der if those G‑O-F exper­i­ments were con­nect­ed to the recast­ing of remde­sivir as a broad spec­trum antivi­ral.)

Dur­ing the post‑9/11 peri­od of explod­ing gov­ern­ment invest­ments in biode­fense pro­grams, Rums­feld was still hold­ing onto mas­sive amounts of Gilead­’s stock, which was rapid­ly increas­ing in val­ue. What kind of rela­tion­ship did Gilead devel­op with the US biode­fense nation­al secu­ri­ty state dur­ing this peri­od? That seems like an  impor­tant ques­tion at this point in time. 

In FTR #1136, we not­ed that the med­ical and sci­en­tif­ic inter­ests in charge of Lyme Dis­ease treat­ment and diag­no­sis were not only finan­cial ben­e­fi­cia­ries of the ther­a­peu­tic sta­tus quo, but were also tasked with dis­cred­it­ing Lyme patients and physi­cians who chal­lenged that sta­tus quo. In light of the evi­dence that Lyme Dis­ease was the out­growth of bio­log­i­cal war­fare research, the pro­fes­sion­al rela­tion­ship between gov­ern­men­tal insti­tu­tions involved with BW research and biotech­nol­o­gy and phar­ma­ceu­ti­cal firms prof­it­ing from the treat­ment of dis­eases those insti­tu­tions devel­op and deploy is worth con­tem­plat­ing! 

Pre­vi­ous broad­casts have doc­u­ment­ed the skewed, pref­er­en­tial treat­ment of remde­sivir by pow­er­ful polit­i­cal and finan­cial play­ers with sig­nif­i­cant invest­ment in the suc­cess of remde­sivir.

The pro­gram con­cludes with three updates of pre­vi­ous lines of inquiry”

1.–Past pro­grams have high­light­ed pos­si­ble vec­tors into Wuhan for the SARS CoV‑2. We note that there was a work­shop held at the Wuhan lab in ear­ly Novem­ber of 2019, fea­tur­ing sci­en­tists and bio-lab pro­fes­sion­als from around the world. This con­fer­ence may have been among the oppor­tu­ni­ties to spread the virus, and/or a co-vec­tor and/or cross-vec­tor. ” . . . . The work­shop is designed for lab­o­ra­to­ry man­agers and direc­tors, research and lab­o­ra­to­ry staffs main­ly from devel­op­ing coun­tries who plan to car­ry out infec­tious dis­ease research in biosafe­ty facil­i­ties. The work­shop will address key aspects of biosafe­ty and pro­vide prac­ti­cal train­ing in high lev­el biosafe­ty lab­o­ra­to­ries (BSL). This work­shop will invite a group of well-known schol­ars and experts from relat­ed fields at home and abroad to pro­vide the the­o­ret­i­cal and prac­ti­cal cours­es. . . .”
2.–As not­ed in past pro­grams the Wuhan Insti­tute of Virol­o­gy was engaged in bat-borne coro­n­avirus research, which includ­ed the genet­ic mod­i­fi­ca­tion of such organ­isms. That research was a joint U.S./Chinese under­tak­ing, with the U.S. fund­ing com­ing from insti­tu­tions which have front­ed for Amer­i­can intel­li­gence and the Pen­ta­gon. That joint U.S./Chinese under­tak­ing was ter­mi­nat­ed by the Trump admin­is­tra­tion in May! In addi­tion: ” . . . . Many of the sci­en­tists at the Wuhan Insti­tute of Virol­o­gy have been trained by the U.S. government’s PREDICT project. . . . USAID’s PREDICT project . . . will end this Sep­tem­ber after 10 years and two six-month exten­sions as USAID launch­es a new project that applies the data PREDICT col­lect­ed. . . .”
3.–Other broad­casts have explored the Wuhan World Mil­i­tary Games–a mil­i­tary sports competition–as a pos­si­ble vec­tor­ing vehi­cle. We update that path of inquiry with dis­cus­sion of the U.S. del­e­ga­tion as a pos­si­ble vec­tor­ing agent for the spread of the dis­ease in the U.S. ” . . . . Con­trary to the Pentagon’s insis­tence, how­ev­er, an inves­ti­ga­tion of COVID-19 cas­es in the mil­i­tary from offi­cial and pub­lic source mate­ri­als shows that a strong cor­re­la­tion exists in COVID-19 cas­es report­ed at U.S. mil­i­tary facil­i­ties that are home bases of mem­bers of the U.S. team that went to Wuhan. Before March 31, when the Pen­ta­gon restrict­ed the release of infor­ma­tion about COVID-19 cas­es at instal­la­tions for secu­ri­ty rea­sons, infec­tions occurred at a min­i­mum of 63 mil­i­tary facil­i­ties where team mem­bers returned after the Wuhan games. Addi­tion­al­ly, the U.S. team used char­tered flights to and from the games via Seat­tle-Taco­ma Inter­na­tion­al Air­port. Wash­ing­ton was one of the ear­li­est states to show a spike in COVID-19. . . .” We also note that the U.S. del­e­ga­tion con­tained: ” . . . . nine pub­lic-affairs offi­cers . . . and two State Depart­ment per­son­nel, accord­ing to DOD doc­u­ments. . . .” “Pub­lic affairs offi­cer” is a com­mon cov­er for CIA per­son­nel.

FTR #1131 Bio-Psy-Op Apocalypse Now, Part 7: Moderna Uber Alles

We begin by Intro­duc­ing the top­ic of Mod­er­na’s SARS Cov‑2 vac­cine as a mon­ey mak­er for both Mod­er­na and as a dri­ver for the mar­ket as a whole, we note last Mon­day’s announce­ment which gen­er­at­ed a major boost in the val­ue of Mod­er­na’s stock and a strong, gen­er­al ral­ly. The lat­ter appar­ent­ly stems from opti­mism that a sucess­ful vac­cine will alle­vi­ate the eco­nom­ic dam­age from Covid-19.

A Mar­ket­Watch piece about the rapid fluc­tu­a­tion of Mod­er­na’s stock under­scores the sig­nif­i­cance of the tim­ing of an announce­ment cast­ing Mod­er­na’s vac­cine tri­al in over­ly opti­mistic light:

1.–Moderna’s CEO (Stephen Ban­cel) and CFO (Lorence Kim) both sold stock on Fri­day, in accor­dance with pre­arranged trans­ac­tions. Bear in mind, that (as dis­cussed in FTR #1130) Mod­er­na’s stock was trad­ing at $23.46 at the begin­ning of the year, and the company–which has nev­er mar­ket­ed a vaccine–was the ben­e­fi­cia­ry of $483 mil­lion dol­lars in fed­er­al fund­ing ear­li­er in the year.) ” . . . . On Fri­day, Ban­cel sold 11,046 shares at a weight­ed aver­age price of $65.56 for about $724,200, as part of a pre­de­ter­mined trad­ing plan adopt­ed Dec. 28, 2018, accord­ing to a Form 4 fil­ing with the Secu­ri­ties and Exchange Com­mis­sion. He also dis­posed of 1,577 shares as part of a ‘bona fide’ gift. . . . Also, on Fri­day, Kim sold 20,000 shares at a weight­ed aver­age price of $65.53 for about $1.31 mil­lion, as part of a pre­de­ter­mined trad­ing plan. . . .”

2.–Kim also simul­ta­ne­ous­ly bought and sold shares of his firm for a net prof­it of $16.79 mil­lion on Mon­day, the day of an over­ly opti­mistic announce­ment by Mod­er­na. The for­tu­itous­ly timed Mod­er­na announce­ment made the fir­m’s CFO rough­ly $4 mil­lion: ” . . . . On Mon­day, he [Kim] exer­cised options to buy 241,000 shares at a weight­ed aver­age price of $12.45 for about $3 mil­lion, also as part of a pre­de­ter­mined plan. At the same time, Kim exe­cut­ed sales of 241,000 shares, at a weight­ed aver­age price of $82.12 for about $19.79 mil­lion. That means Kim net­ted about $16.79 mil­lion on the simul­ta­ne­ous buy and sale of shares. . . . with Monday’s stock price surge fol­low­ing the announce­ment of ear­ly data on its vac­cine can­di­date poten­tial­ly adding $4 mil­lion to Kim’s cof­fers. . . .”

3.–The above-ref­er­enced announce­ment by Mod­er­na led to a dra­mat­ic increase in Mod­er­na’s stock and boost­ed the mar­ket as a whole. Mod­er­na announced that evening that it would sell $1.34 bil­lion in stock to help its vac­cine oper­a­tion: ” . . . . Shares of Mod­er­na closed at a record high of $80.00 on Mon­day after the com­pa­ny released a slice of pos­i­tive inter­im clin­i­cal data from the first phase of its COVID-19 vac­cine tri­al. That night it announced it would sell $1.34 bil­lion in stock to help fund man­u­fac­tur­ing costs asso­ci­at­ed with the exper­i­men­tal COVID-19 vac­cine. . . .”

4.–Moderna’s stock nose­dived at the end of the trad­ing day on Tues­day, due to a crit­i­cal arti­cle from Stat News: ” . . . . The stock took a nose dive on Tues­day, clos­ing at $71.67, like­ly due in some degree to a Stat News sto­ry that ques­tioned a lack of clin­i­cal clar­i­ty in the data it pro­vid­ed to investors. . . .”
Mod­er­na’s announce­ment was crit­i­cal­ly assessed by Stat News, which point­ed out that the results were incom­plete at best: ” . . . . In a clin­i­cal-tri­al data dis­clo­sure on Mon­day, Mod­er­na shared that eight out of 45 par­tic­i­pants in its COVID-19 vac­cine study devel­oped neu­tral­iz­ing anti­bod­ies, a deci­sion that Stat’s Helen Bran­swell described as a ‘rea­son for cau­tion.’ It didn’t share infor­ma­tion about the immune response to the exper­i­men­tal vac­cine in the remain­ing 37 par­tic­i­pants. . . .”

5.–Nonetheless, Mod­er­na’s stock–bolstered by gov­ern­ment investment–has been on a dra­mat­ic upward swing: ” . . . . The company’s stock was up 3.8% in trad­ing on Wednes­day. Year-to-date, it has soared 270.2%, even though the com­pa­ny has no approved prod­ucts. . . .”

There are seri­ous ques­tions about the sub­stance of Mod­er­na’s state­ment:

1.–Moderna’s much tout­ed report on its vaccine—which trig­gered an upsurge in the mar­kets on Monday—appears to have been incom­plete, at best, and pur­pose­ful­ly decep­tive, at worst. “ . . . . While Mod­er­na blitzed the media, it revealed very lit­tle infor­ma­tion — and most of what it did dis­close were words, not data.. . . . If you ask sci­en­tists to read a jour­nal arti­cle, they will scour data tables, not cor­po­rate state­ments. With sci­ence, num­bers speak much loud­er than words. Even the fig­ures the com­pa­ny did release don’t mean much on their own, because crit­i­cal infor­ma­tion — effec­tive­ly the key to inter­pret­ing them — was with­held. . . .”

2.–Part of the rea­son for alarm and skep­ti­cism con­cerns the behav­ior of the NIAID—whose direc­tor is Antho­ny Fau­ci: “ . . . . The Nation­al Insti­tute for Aller­gy and Infec­tious Dis­eases has part­nered with Mod­er­na on this vac­cine. Sci­en­tists at NIAID made the vaccine’s con­struct, or pro­to­type, and the agency is run­ning the Phase 1 tri­al. This week’s Mod­er­na read­out came from the ear­li­est of data from the NIAID-led Phase 1. NIAID doesn’t hide its light under a bushel. The insti­tute gen­er­al­ly trum­pets its find­ings, often offer­ing direc­tor Antho­ny Fau­ci . . . or oth­er senior per­son­nel for inter­views. But NIAID did not put out a press release Mon­day and declined to pro­vide com­ment on Moderna’s announce­ment. . . .”

3.–To begin with, Moderna’s announce­ment was only sta­tis­ti­cal­ly sub­stan­tive for 8 of the 45 vol­un­teer sub­jects: “ . . . . The company’s state­ment led with the fact that all 45 sub­jects (in this analy­sis) who received dos­es of 25 micro­grams (two dos­es each), 100 micro­grams (two dos­es each), or a 250 micro­grams (one dose) devel­oped bind­ing anti­bod­ies. Lat­er, the state­ment indi­cat­ed that eight vol­un­teers — four each from the 25-micro­gram and 100-micro­gram arms — devel­oped neu­tral­iz­ing anti­bod­ies. Of the two types, these are the ones you’d real­ly want to see. We don’t know results from the oth­er 37 tri­al par­tic­i­pants. . . .”

4.–It is pos­si­ble that neu­tral­iz­ing anti­bod­ies may have been devel­oped in the 37 test sub­jects whose data was not released because the test­ing process is exact­ing. Still the state­ment war­rants cau­tion, at the least. “ . . . . This doesn’t mean that they didn’t devel­op neu­tral­iz­ing antibodies.Testing for neu­tral­iz­ing anti­bod­ies is more time-con­sum­ing than oth­er anti­body tests and must be done in a biose­cu­ri­ty lev­el 3 lab­o­ra­to­ry. Mod­er­na dis­closed the find­ings from eight sub­jects because that’s all it had at that point. Still, it’s a rea­son for cau­tion . . . .”

5.–In addi­tion, the age of the sub­jects was not released and that is rel­e­vant. “ . . . . Sep­a­rate­ly, while the Phase 1 tri­al includ­ed healthy vol­un­teers ages 18 to 55 years, the exact ages of these eight peo­ple are unknown. If, by chance, they most­ly clus­tered around the younger end of the age spec­trum, you might expect a bet­ter response to the vac­cine than if they were most­ly from the senior end of it. And giv­en who is at high­est risk from the SARS-CoV­‑2 coro­n­avirus, pro­tect­ing old­er adults is what Covid-19 vac­cines need to do. . . .”

6.–In addi­tion, there was no data released as to the dura­bil­i­ty of the neu­tral­iz­ing anti­bod­ies. If, for the sake of argu­ment, they are not long-last­ing, the util­i­ty of the vac­cine is neg­li­gi­ble. “ . . . . The report of neu­tral­iz­ing anti­bod­ies in sub­jects who were vac­ci­nat­ed comes from blood drawn two weeks after they received their sec­ond dose of vac­cine. Two weeks. ‘That’s very ear­ly. We don’t know if those anti­bod­ies are durable,’ said Anna Durbin, a vac­cine researcher at Johns Hop­kins Uni­ver­si­ty. . . .”

7.–Still anoth­er point of contention/alarm con­cerns the vari­abil­i­ty in neu­tral­iz­ing anti­bod­ies among recov­ered patients: “ . . . . But stud­ies have shown anti­body lev­els among peo­ple who have recov­ered from the ill­ness vary enor­mous­ly; the range that may be influ­enced by the sever­i­ty of a person’s dis­ease. John ‘Jack’ Rose, a vac­cine researcher from Yale Uni­ver­si­ty, point­ed STAT to a study from Chi­na that showed that, among 175 recov­ered Covid-19 patients stud­ied, 10 had no detectable neu­tral­iz­ing anti­bod­ies. Recov­ered patients at the oth­er end of the spec­trum had real­ly high anti­body lev­els. So though the com­pa­ny said the anti­body lev­els induced by vac­cine were as good as those gen­er­at­ed by infec­tion, there’s no real way to know what that com­par­i­son means. . . .”

8.–It is less than encour­ag­ing that Mod­er­na dis­closed that more rel­e­vant data will be dis­closed in a report to be released in con­junc­tion with NIAID: “ . . . . STAT asked Mod­er­na for infor­ma­tion on the anti­body lev­els it used as a com­para­tor. The response: That will be dis­closed in an even­tu­al jour­nal arti­cle from NIAID, which is part of the Nation­al Insti­tutes of Health. . . .”

9.–Ann Durbin was struck by the word­ing of Moderna’s release: “ . . . . Durbin was struck by the word­ing of the company’s state­ment, point­ing to this sen­tence: ‘The lev­els of neu­tral­iz­ing anti­bod­ies at day 43 were at or above lev­els gen­er­al­ly seen in con­va­les­cent sera.’ ‘I thought: Gen­er­al­ly? What does that mean?’ Durbin said. Her ques­tion, for the time being, can’t be answered. . . .”

10.–Jack Rose com­ment­ed on the opaque nature of Moderna’s release: “. . . . Rose said the com­pa­ny should dis­close the infor­ma­tion. ‘When a com­pa­ny like Mod­er­na with such incred­i­bly vast resources says they have gen­er­at­ed SARS‑2 neu­tral­iz­ing anti­bod­ies in a human tri­al, I would real­ly like to see num­bers from what­ev­er assay they are using,’ he said. . . .”

10.–To date, Mod­er­na issues press releas­es, not papers that can be vet­ted by the sci­en­tif­ic com­mu­ni­ty: “ . . . . It doesn’t pub­lish on its work in sci­en­tif­ic jour­nals. What is known has been dis­closed through press releas­es. That’s not enough to gen­er­ate con­fi­dence with­in the sci­en­tif­ic com­mu­ni­ty. ‘My guess is that their num­bers are mar­gin­al or they would say more,’ Rose said about the company’s SARS‑2 vac­cine, echo­ing a sus­pi­cion that oth­ers have about some of the company’s oth­er work. ‘I do think it’s a bit of a con­cern that they haven’t pub­lished the results of any of their ongo­ing tri­als that they men­tion in their press release. They have not pub­lished any of that,’ Durbin not­ed. . . .”

After sum­ma­riz­ing a high­ly tech­ni­cal arti­cle warn­ing that of the pos­si­ble con­se­quences of intro­duc­ing a SARS Cov‑2 vac­cine that gen­er­ates inad­e­quate­ly high lev­els of anti­bod­ies, we detail a 2016 STAT News arti­cle about Mod­er­na high­lights a num­ber of areas of con­cern, giv­en the speed and rel­a­tive­ly opaque nature of the poten­tial intro­duc­tion of its Covid-19 vac­cine.

The financ­ing of the com­pa­ny by DARPA, and Mon­cef Slaoui’s join­ing with Four Star Gen­er­al Per­na (ele­vat­ed by the Chair­man of the Joint Chiefs of Staff, Gen­er­al Mark A. Mil­ley) are of addi­tion­al con­cern.

1.–As of 2016, Mod­er­na had the largest val­u­a­tion of any pri­vate biotech firm and for­mer employ­ees felt that Mod­er­na prized mon­ey over sci­ence. Note that, as will be reviewed lat­er in the pro­gram, its stock has risen expo­nen­tial­ly as a result of the injec­tion of hun­dreds of mil­lions of dol­lars. Bear in mind that Mod­er­na has also been under­writ­ten by DARPA. “ . . . . Mod­er­na is worth more than any oth­er pri­vate biotech in the US, and for­mer employ­ees said they felt that Ban­cel prized the company’s ever-increas­ing val­u­a­tion, now approach­ing $5 bil­lion, over its sci­ence. . . .”

2.–Moderna has main­tained a cul­ture of secre­cy, which in 2016, applied to the first two prod­ucts under­go­ing phase 1 tri­als: “ . . . . Mod­er­na just moved its first two poten­tial treat­ments — both vac­cines — into human tri­als. In keep­ing with the cul­ture of secre­cy, though, exec­u­tives won’t say which dis­eases the vac­cines tar­get, and they have not list­ed the stud­ies on the pub­lic fed­er­al reg­istry, ClinicalTrials.gov. List­ing is option­al for Phase 1 tri­als, which are meant to deter­mine if a drug is safe, but most com­pa­nies vol­un­tar­i­ly dis­close their work. . . .”

3.–Protein ther­a­py has been a dri­ving eco­nom­ic and ther­a­peu­tic fac­tor in the phar­ma­ceu­ti­cal busi­ness: “ . . . . For decades, com­pa­nies have endeav­ored to craft bet­ter and bet­ter pro­tein ther­a­pies, lead­ing to new treat­ments for can­cer, autoim­mune dis­or­ders, and rare dis­eases. Such ther­a­pies are cost­ly to pro­duce and have many lim­i­ta­tions, but they’ve giv­en rise to a multi­bil­lion-dol­lar indus­try. The anti-inflam­ma­to­ry Humi­ra, the world’s top drug at $14 bil­lion in sales a year, is a shin­ing exam­ple of pro­tein ther­a­py. . . .”

4.–Moderna aims at doing an end run around that tech­nol­o­gy with the injec­tion of mRNA (mes­sen­ger RNA) or DNA. This is a risky tech­nol­o­gy: “ . . . . Moderna’s tech­nol­o­gy promised to sub­vert the whole field, cre­at­ing ther­a­peu­tic pro­teins inside the body instead of in man­u­fac­tur­ing plants. The key: har­ness­ing mes­sen­ger RNA, or mRNA. . . . . It’s high­ly risky. Big phar­ma com­pa­nies had tried sim­i­lar work and aban­doned it because it’s exceed­ing­ly hard to get RNA into cells with­out trig­ger­ing nasty side effects. . . . .”

5.–CEO Ban­cel has main­tained the company’s cul­ture of secre­cy: “ . . . . Under Ban­cel, Mod­er­na has been loath to pub­lish its work in Sci­ence or Nature, but enthu­si­as­tic to her­ald its poten­tial on CNBC and CNN, tak­ing part in seg­ments on the world’s most dis­rup­tive com­pa­niesand the poten­tial “cure for can­cer.” . . .”

6.–Moderna had dra­con­ian atti­tude toward employ­ees from its incep­tion: “ . . . . From the begin­ning, Ban­cel made clear that Moderna’s sci­ence sim­ply had to work. And that any­one who couldn’t make it work didn’t belong. The ear­ly Mod­er­na was a chaot­ic, unpre­dictable work­place, accord­ing to for­mer employ­ees. One recalls find­ing him­self out of a job when a quick-turn­around exper­i­ment failed to pan out. Anoth­er helped train a group of new hires only to real­ize they were his replace­ments. . . .”

7.–Joe Bolen exem­pli­fied the treat­ment Mod­er­na met­ed out: “ . . . . Most stun­ning to employ­ees was the abrupt depar­ture of Joseph Bolen, who came aboard in 2013 to lead Moderna’s R&D efforts. Bolen was a big-name hire in biotech cir­cles, an expe­ri­enced chief sci­en­tif­ic offi­cer who had guid­ed Mil­len­ni­um Phar­ma­ceu­ti­cals to FDA approval for a block­buster can­cer drug. . . ‘No sci­en­tist in his right mind would leave that job unless there was some­thing wrong with the sci­ence or the per­son­nel,” said a per­son close to the com­pa­ny at the time.’ . . .”

8.–Bolen had com­pa­ny: “ . . . . Bolen wasn’t alone. Chief Infor­ma­tion Offi­cer John Reyn­ders joined in 2013 to make Mod­er­na what he called the world’s “first ful­ly dig­i­tal biotech,”only to step down a year lat­er. Michael Morin, brought in to lead Moderna’s sci­en­tif­ic efforts in can­cer in 2014, last­ed less than 18 months. As did Greg Licholai, hired in 2015 to direct the company’s projects in rare dis­eases. The lat­ter two key lead­er­ship posi­tions remain unfilled. . . .”

9.–The expla­na­tion of CFO Lorence Kim is less than reas­sur­ing from the stand­point of prod­uct safe­ty and reli­a­bil­i­ty: “ . . . . ‘We force every­one to grow with the com­pa­ny at unprece­dent­ed speed,’ Mod­er­na Chief Finan­cial Offi­cer Lorence Kim said. ‘Some peo­ple grow with the com­pa­ny; oth­ers don’t.’ . . .”

10.–Beginning in 2013, Mod­er­na part­nered with a series of phar­ma­ceu­ti­cal giants, includ­ing AstraZeneca, which has been select­ed to devel­op a Covid-19 vac­cine: “ . . . . That’s when Mod­er­na — which had just 25 employ­ees — signed a stag­ger­ing $240 mil­lion part­ner­ship with UK phar­ma­ceu­ti­cal giant AstraZeneca. It was the most mon­ey phar­ma had ever spent on drugs that had not yet been test­ed in humans. . . .”

11.–The firm has been lav­ish­ly cap­i­tal­ized: “ . . . . In ear­ly 2015, Mod­er­na dis­closed a $450 mil­lion financ­ing round, the largest ever for a pri­vate biotech com­pa­ny. This month, the com­pa­ny broke its own record, rais­ing anoth­er $474 mil­lion. . . . Though it has yet to reveal data from a sin­gle clin­i­cal tri­al, Mod­er­na is now val­ued at $4.7 bil­lion, accord­ing to Pitch­book. . . .”

12.–Initially, Mod­er­na aimed at devel­op­ing prod­ucts that would be admin­is­tered for a peri­od of years: “ . . . . From the start, Mod­er­na her­ald­ed its abil­i­ty to pro­duce pro­teins with­in cells, which could open up a world of ther­a­peu­tic tar­gets unreach­able by con­ven­tion­al drugs. The most rev­o­lu­tion­ary treat­ments, which could chal­lenge the multi­bil­lion-dol­lar mar­ket for pro­tein ther­a­py, would involve repeat­ed dos­es of mRNA over many years, so a patient’s body con­tin­ued to pro­duce pro­teins to keep dis­ease at bay. . . .”

13.–Instead of pro­duc­ing treat­ments that would be admin­is­tered over a peri­od of years, the com­pa­ny focused on vac­cines: “ . . . . But Moderna’s first human tri­als aren’t so ambi­tious, focus­ing instead on the crowd­ed field of vac­cines, where the com­pa­ny has only been work­ing since 2014. . . . The choice to pri­or­i­tize vac­cines came as a dis­ap­point­ment to many in the com­pa­ny, accord­ing to a for­mer man­ag­er. The plan had been to rad­i­cal­ly dis­rupt the biotech indus­try, the man­ag­er said, so ‘why would you start with a clin­i­cal pro­gram that has very lim­it­ed upside and lots of com­pe­ti­tion?’” . . . .”

14.–The answer to Moderna’s focus on vac­cines may be due to issues of prod­uct safe­ty: “ . . . Deliv­ery — actu­al­ly get­ting RNA into cells — has long bedev­iled the whole field. On their own, RNA mol­e­cules have a hard time reach­ing their tar­gets. They work bet­ter if they’re wrapped up in a deliv­ery mech­a­nism, such as nanopar­ti­cles made of lipids. But those nanopar­ti­cles can lead to dan­ger­ous side effects, espe­cial­ly if a patient has to take repeat­ed dos­es over months or years. . . .”

15.–Vaccines will only admin­is­ter mRNA at the time of vac­ci­na­tion, rather than over a long peri­od of time: “ . . . . ‘I would say that mRNA is bet­ter suit­ed for dis­eases where treat­ment for short dura­tion is suf­fi­cient­ly cura­tive, so the tox­i­c­i­ties caused by deliv­ery mate­ri­als are less like­ly to occur,’ said Katal­in Karikó, a pio­neer in the field who serves as a vice pres­i­dent at BioN­Tech. . . That makes vac­cines the low­est hang­ing fruit in mRNA, said Franz-Wern­er Haas, CureVac’s chief cor­po­rate offi­cer. ‘From our point of view, it’s obvi­ous why [Mod­er­na] start­ed there,’ he said.’ . . .”

16.–Moderna’s expla­na­tion for its focus on vac­cines is not reassuring—the speed with which it can pro­ceed to human tri­als. The firm’s secre­cy has gen­er­at­ed alarm: “ . . . . Mod­er­na said it pri­or­i­tized vac­cines because they pre­sent­ed the fastest path to human tri­als, not because of set­backs with oth­er projects. ‘The notion that [Mod­er­na] ran into dif­fi­cul­ties isn’t borne in real­i­ty,’ said Afeyan. But this is where Moderna’s secre­cy comes into play: Until there’s pub­lished data, only the com­pa­ny and its part­ners know what the data show. Every­one out­side is left guess­ing — and, in some cas­es, wor­ry­ing that Mod­er­na won’t live up to its hype. . . .”

17.–Moderna applies soft­ware and a busi­ness mod­el derived from Tes­la, Ama­zon and Uber: “ . . . . Mod­er­na has pio­neered an auto­mat­ed sys­tem mod­eled on the soft­ware Tes­la uses to man­age orders, Ban­cel said: Sci­en­tists sim­ply enter the pro­tein they want a cell to express, and testable mRNA arrives with­in weeks. . . . That has always been part of the plan, for­mer employ­ees said, point­ing to Bancel’s fas­ci­na­tion with the tech indus­try. Uber and Ama­zon were not the first to come up with their respec­tive busi­ness ideas, but they were the ones that built enough scale to ward off com­pe­ti­tion. And Mod­er­na is posi­tion­ing itself to do the same in mRNA. . . .”

Mon­cef Slaoui’s  opti­mistic state­ment on the Fri­day before the Mon­day announce­ment, presents impor­tant con­text for Moderna’s Mon­day announce­ment. That announce­ment moved mar­kets based on inad­e­quate data. “Oper­a­tion Warp Speed” (head­ed by Slaoui) sug­gests that can­di­date Trump  is very inter­est­ed in those pre­lim­i­nary results as well. 

Eliz­a­beth War­ren scored Slaoui’s con­flict of interest–a con­sid­er­a­tion that will be dis­cussed at length: ” . . . . Fol­low­ing Mon­cef Slaoui’s Fri­day appoint­ment as a co-leader of the Warp Speed pro­gram, he’s set to sell about 155,000 shares in Mod­er­na, accord­ing to press reports. They were worth an esti­mat­ed $10 mil­lion Fri­day, but after Monday’s stock run-up on pos­i­tive ear­ly data, they’re now val­ued at about $12.4 mil­lion. . . . Fol­low­ing Slaoui’s selec­tion, Sen. Eliz­a­beth War­ren tweet­ed that it’s a ‘huge con­flict of inter­est’ for him to keep the Mod­er­na stock as he assumes the new role. She said he should ‘divest imme­di­ate­ly.’ In a now-delet­ed tweet, Slaoui respond­ed that there ‘is no con­flict of inter­est, and there nev­er has been,’ Busi­ness Insid­er reports. . . .”

Even after agree­ing to sell his Mod­er­na stock, Slaoui’s invest­ments raise alarm­ing questions–note that he is a “ven­ture cap­i­tal­ist” and a long­time for­mer exec­u­tive at Glaxo-Smithk­line:

1.–The cir­cum­stances of his appoint­ment will per­mit him to avoid scruti­ny: ” . . . . In agree­ing to accept the posi­tion, Dr. Slaoui did not come on board as a gov­ern­ment employ­ee. Instead, he is on a con­tract, receiv­ing $1 for his ser­vice. That leaves him exempt from fed­er­al dis­clo­sure rules that would require him to list his out­side posi­tions, stock hold­ings and oth­er poten­tial con­flicts. And the con­tract posi­tion is not sub­ject to the same con­flict-of-inter­est laws and reg­u­la­tions that exec­u­tive branch employ­ees must fol­low. . . .”

2.–He will retain a great deal of Glaxo-Smithk­line stock: ” . . . . He did not say how much his GSK shares were worth. When he left the com­pa­ny in 2017, he held about [500,000 in West­ern Print Edi­tion] 240,000 shares and share equiv­a­lents, accord­ing to the drug company’s annu­al report and an analy­sis by the exec­u­tive com­pen­sa­tion firm Equi­lar. . . .”

3.–Further analy­sis of Slaoui’s posi­tion deep­ens con­cern about the integri­ty of the process: ” . . . . ‘This is basi­cal­ly absurd,’ said Vir­ginia Can­ter, who is chief ethics coun­sel for Cit­i­zens for Respon­si­bil­i­ty and Ethics in Wash­ing­ton. ‘It allows for no pub­lic scruti­ny of his con­flicts of inter­est.’ Ms. Can­ter also said fed­er­al law barred gov­ern­ment con­trac­tors from super­vis­ing gov­ern­ment employ­ees. . . . Ms. Can­ter, a for­mer ethics lawyer in the Oba­ma and Clin­ton admin­is­tra­tions, the Secu­ri­ties and Exchange Com­mis­sion and oth­er agen­cies, point­ed out that GSK’s vac­cine can­di­date with Sanofi could wind up com­pet­ing with oth­er man­u­fac­tur­ers vying for gov­ern­ment approval and sup­port. ‘If he retains stock in com­pa­nies that are invest­ing in the devel­op­ment of a vac­cine, and he’s involved in over­see­ing this process to select the safest vac­cine to com­bat Covid-19, regard­less of how won­der­ful a per­son he is, we can’t be con­fi­dent of the integri­ty of any process in which he is involved,’ Ms. Can­ter said. In addi­tion, his affil­i­a­tion with Medicxi could com­pli­cate mat­ters: Two of its investors are GSK and a divi­sion of John­son & John­son, which is also devel­op­ing a poten­tial vac­cine. . . .”

Mod­er­na stands to make bil­lions of dol­lars if their vac­cine goes to mar­ket:

1.–” . . . . What investors are bet­ting on, for Mod­er­na and oth­ers devel­op­ing vac­cines against the SARS-CoV­‑2 virus, is that a third of the devel­oped world’s pop­u­la­tion will get vac­ci­nat­ed every year. That could amount to a $10 bil­lion annu­al busi­ness, at an esti­mat­ed price of $30 per vac­ci­na­tion. . . .”

2.–” . . . . Mor­gan Stan­ley ana­lysts this past week­end sug­gest­ed that pric­ing might start at $5 to $10 a dose dur­ing this first pan­dem­ic cri­sis, then rise to a range of $13 to $30 for pre­ven­tive dos­es in future years. But at BMO Cap­i­tal Mar­kets, ana­lyst George Farmer spec­u­lat­ed that Mod­er­na could start charg­ing $125 per treat­ment in the U.S. mar­ket and raise that price over time to $200. . . . ”

We close the pro­gram with a reminder of the extent to which fed­er­al fund­ing dri­ves the val­ue of Mod­er­na: ” . . . . ‘Instead of wait­ing for the data and then scal­ing up with man­u­fac­tur­ing process … we can make as many dos­es as we can. We are doing both in par­al­lel,’ he said. The com­pa­ny plans to hire up to 150 peo­ple to sup­port the effort. Ban­cel said the com­pa­ny ‘couldn’t have done this’ with­out the fund­ing com­mit­ment from the Bio­med­ical Advanced Research and Devel­op­ment Author­i­ty, which is part of the Depart­ment of Health and Human Ser­vices. . . .”

Preview of “Walkin’ the Coronavirus”

In Ser­pen­t’s Walk–which we have dis­cussed for decades–the SS go under­ground (which they did), buy into the opin­ion-form­ing media (which they did) and, infil­trate the mil­i­tary (which they have done), and, after a ter­ror­ist attack by genet­i­cal­ly-engi­neered virus­es dec­i­mates large parts of the Unit­ed States, mar­tial law is declared and the Nazis take over. NB: we do not know if “cross-vec­tor­ing” is occur­ring with the Covid-19 virus, how­ev­er that is some­thing to be con­tem­plat­ed and researched. From “Ser­pen­t’s Walk: ” . . . . ‘Pacov con­sists of two sep­a­rate re-work­ings of two DNA chains of exist­ing virus­es. It’s a pig­gy-back weapon, a two-stage oper­a­tion. You send in the first stage. The vec­tors . . . agents of trans­mis­sion . . . for Pacov‑1 are exten­sive. It trav­els through the air, the water, or direct­ly from per­son-to-per­son and is high­ly con­ta­gious. It spreads for hun­dreds of miles, if con­di­tions are opti­mal.  Pacov‑1 pro­duces only a mild, flu-like infec­tion that dis­ap­pears with­in a day or two. Pub­lic health author­i­ties would over­look it, nev­er con­sid­er it a seri­ous epi­dem­ic, and even if they did they’d have to look care­ful­ly to iso­late it. Once a vic­tim is over the ‘flu,’ Pacov‑1 becomes dor­mant and almost unde­tectable. A month or two lat­er, you send in the sec­ond stage: Pacov‑2 is also a virus, just as con­ta­gious as the first, and just as harm­less by itself. It reacts with Pacov‑1 to pro­duce a pow­er­ful coag­u­lant. . . . you die with­in three min­utes. No warn­ing, no vac­cine, no cure. Those not exposed to both stages remain unharmed. . . . Pacov‑2 goes inert, like Pacov‑1 with­in a week or two. Then you get your victim’s coun­try, all his prop­er­ty, in undam­aged con­di­tion. . . . and a lot of corpses to bury.’ . . . .” We note that, although a “coag­u­lant” is not caus­ing the phe­nom­e­non, blood clots are indeed one of the many symp­toms of the Covid-19: ” . . . . Doc­tors in hot spots across the globe have begun to report an unex­pect­ed preva­lence of blood clot­ting among COVID cas­es, in what could pose a per­fect storm of poten­tial­ly fatal risk fac­tors. . . . It’s grow­ing so com­mon with severe COVID cas­es, doc­tors are rec­og­niz­ing it as a new pat­tern of clot­ting called COVID-19-asso­ci­at­ed coag­u­lopa­thy, or CAC, which is notably asso­ci­at­ed with high inflam­ma­to­ry mark­ers in the blood, like D‑dimer and fib­rino­gen. . . . ‘In the begin­ning of the out­break, we start­ed only giv­ing them med­i­cine to pre­vent clots. We saw that it was­n’t enough,’ Dr. Cristi­na Abad, an anes­the­si­ol­o­gist at Hos­pi­tal Clínicos San Car­los in Madrid, told ABC News. ‘They start­ed hav­ing pul­monary embolisms, so we start­ed [full] anti­co­ag­u­la­tion on every­one.’ . . .”

Provocation: Covid-19 as a False Flag “Bio-Reichstag Fire” (Updated on 4/22/2020)

In FTR #1126, we exam­ined the Trump admin­is­tra­tion and GOP’s exploita­tion of the Covid-19 out­break as a cam­paign tac­tic and right-wing hints that the virus escaped from a Chi­nese bio­log­i­cal war­fare lab­o­ra­to­ry. Now, Ger­many, France and Britain are join­ing with the Trump admin­is­tra­tion and the GOP in hint­ing that the coro­n­avirus escaped from a Chi­nese bio­log­i­cal war­fare lab­o­ra­to­ry. As a “Ger­man For­eign Pol­i­cy” arti­cle notes, the tone of Amer­i­can, British, French and Ger­man rhetoric con­cern­ing Covid-19 is rem­i­nis­cent of the delib­er­ate dis­in­for­ma­tion that led to the inva­sion of Iraq in 2002. A) ” . . . . Last week­end, US Pres­i­dent Don­ald Trump warned the Peo­ple’s Repub­lic that it should face con­se­quences if it was ‘know­ing­ly respon­si­ble’ for the spread of the pan­dem­ic. Wash­ing­ton is simul­ta­ne­ous­ly spread­ing delib­er­ate rumors that the virus could have orig­i­nat­ed in a Chi­nese lab­o­ra­to­ry. Where­as, sci­en­tists vehe­ment­ly refute the alle­ga­tions, Ger­man For­eign Min­is­ter Heiko Maas declared, he ‘does not want to exclude’ that the WHO will have to deal with these issues. On Mon­day, Chan­cel­lor Angela Merkel called on Bei­jing to show ‘trans­paren­cy’ on the issue. . . .”; B) ” . . . . At the same time delib­er­ate rumors are being spread in the Unit­ed States that the Covid-19 virus could have orig­i­nat­ed in a Chi­nese lab­o­ra­to­ry — pos­si­bly in bioweapons lab. The US gov­ern­ment indi­cat­ed that it does not rule out this pos­si­bil­i­ty; US intel­li­gence ser­vices are cur­rent­ly inves­ti­gat­ing the issue. Par­tic­u­lar­ly giv­en the lie about Iraq’s alleged weapons of mass destruc­tion, such an alle­ga­tion must be per­ceived as a threat to lend legit­i­ma­cy to new aggres­sions. . . .”; C) ” . . . . Already last week, Ger­man media organs have increas­ing­ly been call­ing Chi­na the ‘cul­prit’ behind the Covid-19 pan­dem­ic out­break. Under the head­line ‘what Chi­na already owes us,’ Ger­many’s Springer press even called for ‘repa­ra­tions.’ (german-foreign-policy.com reported.[5]) Lead­ing British and French politi­cians have expressed sim­i­lar views. British For­eign Min­is­ter Dominic Raab has repeat­ed­ly declared that Chi­na will be held respon­si­ble for the Covid-19 pan­dem­ic. French Pres­i­dent Emmanuel Macron has now joined the cam­paign. Regard­ing the pan­demic’s alleged ori­gin, he declared, ‘there are clear­ly things that have hap­pened’ in Chi­na ‘that we don’t know about.’[6] It is not clear how Macron can know some­thing exists that he does not know about. It is how­ev­er clear that he seeks to impli­cate Bei­jing. . . .” In fact–as we have seen, the DARPA has been doing exten­sive research into bat-borne coro­n­avirus­es. In addi­tion, Fort Det­rick was shut down in ear­ly August of 2019 for safe­ty vio­la­tions.

Supplement to The Magic Virus Theory

As dis­cussed in FTR #1124–among oth­er programs–it is now pos­si­ble to cre­ate ANY virus from scratch, using “mail-order” or “design­er” genes. Sad­ly pre­dictable jour­nal­is­tic bro­mides that the Covid-19 coro­n­avirus could not have been/was not made in a lab­o­ra­to­ry fly in the face of bio-tech­nol­o­gy that has exist­ed for 20 years. In FTR #282–recorded in May of 2001–we not­ed the ter­ri­ble sig­nif­i­cance of the devel­op­ment of such “Design­er Gene” tech­nol­o­gy. A BBC sto­ry from 1999 high­lights the fears of experts that the advent of such tech­nol­o­gy could enable the devel­op­ment of eth­no-spe­cif­ic bio­log­i­cal weapons: ” . . . . Advances in genet­ic knowl­edge could be mis­used to devel­op pow­er­ful bio­log­i­cal weapons that could be tai­lored to strike at spe­cif­ic eth­nic groups, the British Med­ical Asso­ci­a­tion has warned. A BMA report Biotech­nol­o­gy, Weapons and Human­i­ty says that con­cert­ed inter­na­tion­al action is nec­es­sary to block the devel­op­ment of new, bio­log­i­cal weapons. It warns the win­dow of oppor­tu­ni­ty to do so is very nar­row as tech­nol­o­gy is devel­op­ing rapid­ly and becom­ing ever more acces­si­ble. ‘Recipes’ for devel­op­ing bio­log­i­cal agents are freely avail­able on the Inter­net, the report warns. . . . The BMA report warns that legit­i­mate research into micro­bi­o­log­i­cal agents and genet­i­cal­ly tar­get­ed ther­a­peu­tic agents could be dif­fi­cult to dis­tin­guish from research geared towards devel­op­ing more effec­tive weapons. . . . Dr Vivi­enne Nathanson, BMA Head of Health Pol­i­cy Research said: . . . ‘Biotech­nol­o­gy and genet­ic knowl­edge are equal­ly open to this type of malign use. Doc­tors and oth­er sci­en­tists have an impor­tant role in pre­ven­tion. They have a duty to per­suade politi­cians and inter­na­tion­al agen­cies such as the UN to take this threat seri­ous­ly and to take action to pre­vent the pro­duc­tion of such weapons.’ . . . ”

FTR #1126 Bio-Psy-Op Apocalypse Now, Part 2: The Democracy-Killing Virus

We begin a series of pro­grams high­light­ing var­i­ous aspects of the “three-dimen­sion­al chess” aspect of the Covid-19 “bio-psy-op” we feel is under­way. Actu­al­ly six or sev­en dimen­sion­al chess might be a bet­ter way of express­ing this ana­lyt­i­cal con­cept.

It is of para­mount impor­tance for listeners/readers to under­stand that the con­cep­tu­al break­down is for cog­ni­tive clar­i­ty only. The bio-psy-op” is mul­ti-dimen­sion­al in its entire­ty and must be under­stood to be a type of “fascist/totalitarian lasagna” with many lay­ers to be con­sumed.

In this pro­gram, we present ways in which the Covid-19 out­break is sub­vert­ing democ­ra­cy, both inside and out­side of the Unit­ed States.

Although he has only flirt­ed with exer­cis­ing them, to date, Trump does indeed have some emer­gency pow­ers that can be invoked to fur­ther his agen­da” ” . . . . The most notable aspect of pres­i­den­tial emer­gency action doc­u­ments might be their extreme secre­cy. It’s not uncom­mon for the gov­ern­ment to clas­si­fy its plans or activ­i­ties in the area of nation­al secu­ri­ty. . . . By con­trast, we know of no evi­dence that the exec­u­tive branch has ever con­sult­ed with Con­gress — or even informed any of its mem­bers — regard­ing the con­tents of pres­i­den­tial emer­gency action doc­u­ments. . . . That is a dan­ger­ous state of affairs. The coro­n­avirus pan­dem­ic is fast becom­ing the most seri­ous cri­sis to face this coun­try since World War II. And it is hap­pen­ing under the watch of a pres­i­dent who has claimed that Arti­cle II of the Con­sti­tu­tion gives him ‘the right to do what­ev­er I want.’ It is not far-fetched to think that we might see the deploy­ment of these doc­u­ments for the first time and that they will assert pres­i­den­tial pow­ers beyond those grant­ed by Con­gress or rec­og­nized by the courts as flow­ing from the Con­sti­tu­tion. . . .”

Next, we add that the Bio-Psy-Op Apoc­a­lypse is spawn­ing total­i­tar­i­an manifestations–not surprisingly–at the Depart­ment of Jus­tice head­ed by “ex” CIA offi­cer William Barr. ” . . . . The request raised eye­brows because of its poten­tial impli­ca­tions for habeas cor­pus — the con­sti­tu­tion­al right to appear before a judge after arrest and seek release. ‘Not only would it be a vio­la­tion of that, but it says ‘affect­ing pre-arrest,’” said Nor­man L. Reimer, exec­u­tive direc­tor of the Nation­al Asso­ci­a­tion of Crim­i­nal Defense Lawyers. ‘So that means you could be arrest­ed and nev­er brought before a judge until they decide that the emer­gency or the civ­il dis­obe­di­ence is over. I find it absolute­ly ter­ri­fy­ing. Espe­cial­ly in a time of emer­gency, we should be very care­ful about grant­i­ng new pow­ers to the gov­ern­ment.’ . . .”

It will come as no sur­prise to vet­er­an lis­ten­ers, the Pen­ta­gon has con­tin­gency plans for vary­ing degrees of gov­ern­men­tal and/or civic dis­abil­i­ty. ” . . . . But Coro­n­avirus is also new ter­ri­to­ry, where the mil­i­tary itself is vul­ner­a­ble and the dis­as­ter sce­nar­ios being con­tem­plat­ed — includ­ing the pos­si­bil­i­ty of wide­spread domes­tic vio­lence as a result of food short­ages — are forc­ing plan­ners to look at what are called ‘extra­or­di­nary cir­cum­stances’. Above-Top Secret con­tin­gency plans already exist for what the mil­i­tary is sup­posed to do if all the Con­sti­tu­tion­al suc­ces­sors are inca­pac­i­tat­ed. Stand­by orders were issued more than three weeks ago to ready these plans, not just to pro­tect Wash­ing­ton but also to pre­pare for the pos­si­bil­i­ty of some form of mar­tial law. . . .”

The mil­i­tary’s con­tin­gency plans have been par­tial­ly acti­vat­ed: ” . . . . While being hit with coro­n­avirus at rates equiv­a­lent to the civil­ian pop­u­la­tion, the U.S. mil­i­tary has acti­vat­ed its ‘defense sup­port of civ­il author­i­ties’ appa­ra­tus, estab­lish­ing liaisons in all 50 states, acti­vat­ing units and com­mand posts, and mov­ing forces to pro­vide med­ical, trans­porta­tion, logis­tics, and com­mu­ni­ca­tions sup­port in New York and Wash­ing­ton states. Lt. Gen. Lau­ra Richard­son, the com­mand of Army North (ARNORTH), has request­ed and received approval for the deploy­ment of ground units in response to the now declared nation­al emer­gency. . . .”

We note, in pass­ing, that, although not in effect at this point, dis­cus­sion of “mar­tial law” are far more than just social media fod­der, to coin a term. ” . . . . Because of so many rumors fly­ing in social media, the Pen­ta­gon estab­lished a ‘rumor con­trol’ web­site to beat down sto­ries of mil­i­tary-imposed quar­an­tines and even mar­tial law. And it said it was going to lim­it details of both the spe­cif­ic num­bers of coro­n­avirus cas­es and oper­a­tional details. . . .”

Mar­tial law dis­cus­sion has been spurred by, among oth­er things, Trump’s rumi­na­tions about what he can and will do: “. . . . Ear­li­er Sat­ur­day, Mr. Trump said that he is con­sid­er­ing declar­ing an ‘enforce­able’ quar­an­tine affect­ing some res­i­dents of the New York met­ro­pol­i­tan area, pos­si­bly includ­ing New Jer­sey and Con­necti­cut. He called the region a ‘hot spot’ of the coro­n­avirus out­break sweep­ing the coun­try. . . . Mr. Trump reit­er­at­ed in his remarks before the send off of the USNS Com­fort that he was con­sid­er­ing a quar­an­tine of the area. The Com­fort is a naval hos­pi­tal boat which is car­ry­ing over 1,000 beds and 1,200 med­ical per­son­nel to New York City. . . . Using active duty troops to enforce a quar­an­tine would require the pres­i­dent to sus­pend the Posse Comi­ta­tus Act, which for­bids the use of the armed ser­vices for law enforce­ment. . . .”

Trump has plen­ty of com­pa­ny: ” . . . . In Hun­gary, a new law has grant­ed Prime Min­is­ter Vik­tor Orban the pow­er to side­step Par­lia­ment and sus­pend exist­ing laws. Mr. Orban, who declared a state of emer­gency this month, now has the sole pow­er to end the emer­gency. Par­lia­ment, where two-thirds of the seats are con­trolled by his par­ty, approved the leg­is­la­tion on Mon­day. . . .‘The draft law is alarm­ing,’ said Daniel Kar­sai, a lawyer in Budapest who said the new leg­is­la­tion had cre­at­ed ‘a big fear’ among Hun­gar­i­ans that ‘the Orban admin­is­tra­tion will be a real dic­ta­tor­ship.’ . . .”

Orban’s Hun­gary has been joined by, among oth­ers, the long-stand­ing British democ­ra­cy: ” . . . . some of the pro­vi­sions . . . . will give the gov­ern­ment unchecked con­trol. The leg­is­la­tion gives sweep­ing pow­ers to bor­der agents and the police, which could lead to indef­i­nite deten­tion and rein­force ‘hos­tile envi­ron­ment’ poli­cies against immi­grants, crit­ics said. ‘Each clause could have had months of debate, and instead it’s all being debat­ed in a few days,’ said Adam Wag­n­er, a lawyer who advis­es a par­lia­men­tary com­mit­tee on human rights. . . . ‘These are eye-water­ing pow­ers that would have not been real­ly imag­in­able in peace­time in this coun­try before,’ said Silkie Car­lo, the direc­tor of Big Broth­er Watch, a rights group. She called the mea­sures ‘dra­con­ian.’ . . . .”

Pri­va­cy is being dra­mat­i­cal­ly cur­tailed under cov­er of com­bat­ting the virus: ” . . . . As Thomas Gaulkin of the Bul­letin of the Atom­ic Sci­en­tists not­ed ear­li­er this month, many Amer­i­cans— often fierce in their objec­tions to per­ceived gov­ern­ment over­reach into their lives—might nor­mal­ly object to dystopi­an images of fly­ing robots polic­ing lock­downs. But these, of course, are not nor­mal times. ‘If drones do begin to hov­er over U.S. streets to help con­trol this pan­dem­ic,’ Gaulkin wrote, ‘it will be yet anoth­er vis­i­ble reminder that we’ve entered a pub­lic health Twi­light Zone where Amer­i­cans have no bet­ter option than to embrace what was once only imag­in­able, and nev­er real.’ . . . ”

The alpha preda­tor of the elec­tron­ic sur­veil­lance land­scape is Peter Thiel’s Palan­tir. They have land­ed two key gov­ern­ment con­tracts in con­nec­tion with the Covid-19 out­break:” . . . . Palan­tir, the $20 bil­lion-val­ued Palo Alto tech com­pa­ny backed by Face­book-fun­der Peter Thiel, has been hand­ed a $17.3 mil­lion con­tract with one of the lead­ing health bod­ies lead­ing the charge against COVID-19. It’s the biggest con­tract hand­ed to a Sil­i­con Val­ley com­pa­ny to assist America’s COVID-19 response, accord­ing to Forbes’ review of pub­lic con­tracts, and comes as oth­er Cal­i­forn­ian giants like Apple and Google try to fig­ure out how best to help gov­ern­ments fight the dead­ly virus. . . . The mon­ey, from the fed­er­al government’s COVID-19 relief fund, is for Palan­tir Gotham licens­es, accord­ing to a con­tract record reviewed by Forbes. That tech­nol­o­gy is designed to draw in data from myr­i­ad sources and, regard­less of what form or size, turn the infor­ma­tion into a coher­ent whole. The ‘plat­form’ is cus­tomized for each client, so it meets with their mis­sion needs, accord­ing to Palan­tir. . . . Palan­tir Gotham is slight­ly dif­fer­ent to Foundry, a new­er prod­uct that’s aimed more at gen­er­al users rather than data sci­ence whizzes, with more automa­tion than Gotham. As Forbes pre­vi­ous­ly report­ed, Foundry is being used by the Cen­ters for Dis­ease Con­trol and Pre­ven­tion (CDC) to ingest infor­ma­tion from all man­ner of hos­pi­tals across Amer­i­ca to see where best to pro­vide more or less resource. . . . Palan­tir is now work­ing with at least 12 gov­ern­ments on their respons­es to coro­n­avirus, accord­ing to two sources with knowl­edge of its COVID-19 work. That includes the U.K.’s Nation­al Health Ser­vice, which is using Foundry for sim­i­lar pur­pos­es as the CDC. . . .”

Exem­pli­fy­ing the mul­ti-dimen­sion­al chess sce­nario in con­nec­tion with the “bio-psy-op” is the GOP’s plan to use the Covid-19 out­break to scape­goat Chi­na and tar the Democ­rats and Joe Biden with the same brush. Of par­tic­u­lar note in this regard is the Steve Bannon‑J. Kyle Bass-Tom­my Hicks, Jr. tri­umvi­rate dis­cussed in–among oth­er programs–FTR #‘s 1111 and 1112.

At the epi­cen­ter of the anti-Chi­na effort, Ban­non is net­worked with Bass, who is asym­met­ri­cal­ly invest­ed with regard to the Hong Kong and Chi­nese economies. Hicks, in turn, is a co-investor with Bass, co-chair­man of the RNC, and one of the prime movers of the inter­a­gency gov­ern­men­tal net­works involved in the anti-Chi­na desta­bi­liza­tion oper­a­tion. This net­worked rela­tion­ship affords investors like Bass and Hicks the ulti­mate posi­tion from which to prof­it from “insid­er” infor­ma­tion. 

The syn­the­sis of covert oper­a­tions and elec­toral pol­i­tics reminds us of the 1952 elec­tion, in which Arthur Bliss Lane occu­pied a key posi­tion in the Cru­sade For Free­dom, as well as the GOP. (We dis­cussed this in AFA #37, and uti­lized infor­ma­tion from, among oth­er sources, Blow­back by Christo­pher Simp­son.

Exem­plary, as well, of the bio-psy-op as syn­the­sis of covert oper­a­tion and polit­i­cal cru­sad­ing is the GOP’s cyn­i­cal manip­u­la­tion of emer­gency appro­pri­a­tions to achieve their long­stand­ing objec­tive of crip­pling state and local gov­ern­ments, as well as dri­ving the Postal Ser­vice into bank­rupt­cy. Pri­va­tiz­ing postal ser­vice has been a right-wing/­GOP objec­tive for a long time. ” . . . . Every­one, and I mean every­one, knows what is real­ly hap­pen­ing: McConnell is try­ing to get more mon­ey for busi­ness­es while con­tin­u­ing to short­change state and local gov­ern­ments. After all, “starve the beast” — forc­ing gov­ern­ments to cut ser­vices by depriv­ing them of resources — has been Repub­li­can strat­e­gy for decades. This is just more of the same. . . . Oh, and Trump per­son­al­ly has ruled out aid for the Postal Ser­vice. . . .”